Author:
Kathrin Dvir,Gliceida M Galarza Fortuna,Nathaly Cortez,Veronica Guerra,Mike Cusnir
Publisher
Peertechz Publications Private Limited
Reference18 articles.
1. 1. Macias RIR, Banales JM, Sangro B, Muntané J, Avila MA, et al. (2018) The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864: 1468-1477. Link: https://bit.ly/2IZJFLV
2. 2. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15: 95-111. Link: https://bit.ly/3lVFGyt
3. 3. The American Cancer Society medical and editorial content team (2020) Survival Rates for Bile Duct Cancer. Link: https://bit.ly/35Virz5
4. 4. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, et al. (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. Link: https://bit.ly/37fok9Z
5. 5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281. Link: https://bit.ly/2UYdaQR
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献